Sakar Healthcare Ltd

Sakar Healthcare Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sakar Healthcare Ltd

₹ 599 5.23%
13 May - close price
sakarhealthcare.com NSE: SAKAR
About

Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products[1]

Key Points

Business Overview:[1][2][3]
SHL, certified by ISO 9001:2015 (BVQI), WHO-GMP, cGMP, and the National Drug Authority, provides comprehensive healthcare and pharmaceutical products. Operating in over 50 countries with 292 registered products and 210 more under registration, SHL partners with 70+ overseas distributors. The company also engages in contract manufacturing for leading domestic brands and direct sales in both domestic and export markets.

Website NSE
  • Market Cap ₹ 1,334 Cr.
  • Current Price ₹ 599
  • High / Low ₹ 662 / 305
  • Stock P/E 43.8
  • Book Value ₹ 146
  • Dividend Yield 0.00 %
  • ROCE 12.7 %
  • ROE 9.99 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 23.1% CAGR over last 5 years

Cons

  • Stock is trading at 4.11 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 7.50% over last 3 years.
  • Promoter holding has decreased over last 3 years: -7.86%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
41 39 34 37 43 41 43 43 50 53 58 70 71
33 30 25 28 32 30 31 32 35 40 46 52 45
Operating Profit 8 9 9 9 11 11 12 12 16 13 11 19 26
OPM % 19% 23% 27% 24% 25% 26% 27% 27% 31% 24% 20% 26% 37%
2 2 1 0 1 0 0 0 0 0 1 1 0
Interest 2 2 2 2 2 1 2 1 4 2 2 2 2
Depreciation 4 5 4 4 5 5 5 5 5 6 6 6 6
Profit before tax 4 4 4 3 5 5 5 5 6 5 5 11 18
Tax % -1% 28% 13% 31% 35% 49% 6% 17% 8% 13% 15% 6% 39%
4 3 4 2 3 2 5 5 6 5 5 10 11
EPS in Rs 2.06 1.49 1.70 0.95 1.43 1.11 2.21 2.06 2.62 2.10 2.04 4.61 4.95
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
83 95 128 133 153 178 252
63 72 99 100 115 128 183
Operating Profit 20 23 29 33 38 50 69
OPM % 24% 24% 23% 25% 25% 28% 27%
2 1 2 5 3 1 2
Interest 2 2 3 6 8 9 8
Depreciation 7 8 10 15 18 21 24
Profit before tax 12 13 19 17 16 22 40
Tax % 21% 19% 20% 24% 27% 19% 23%
10 11 15 13 12 18 30
EPS in Rs 6.43 6.84 8.90 6.70 5.37 7.97 13.70
Dividend Payout % 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 22%
3 Years: 24%
TTM: 42%
Compounded Profit Growth
10 Years: %
5 Years: 23%
3 Years: 34%
TTM: 72%
Stock Price CAGR
10 Years: %
5 Years: 35%
3 Years: 35%
1 Year: 94%
Return on Equity
10 Years: %
5 Years: 8%
3 Years: 8%
Last Year: 10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 15 16 17 19 22 22 22
Reserves 66 83 110 154 241 264 302
17 43 93 119 79 86 55
17 37 47 44 47 43 101
Total Liabilities 115 178 268 336 389 415 481
66 69 205 267 314 309 326
CWIP 13 49 1 6 0 17 4
Investments 0 0 7 3 0 0 0
36 60 55 60 74 90 151
Total Assets 115 178 268 336 389 415 481

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
19 15 36 33 24 34 49
-22 -47 -90 -74 -52 -31 -28
3 32 55 41 27 -3 -21
Net Cash Flow -0 -0 -0 0 0 -0 -0
Free Cash Flow -4 -32 -62 -49 -35 2 21
CFO/OP 110% 67% 120% 113% 72% 73% 77%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 36 48 40 60 50 63 73
Inventory Days 93 112 69 76 121 193 207
Days Payable 46 141 149 129 120 93 153
Cash Conversion Cycle 83 19 -39 7 51 163 127
Working Capital Days 31 1 -11 -6 29 52 44
ROCE % 13% 12% 9% 7% 9% 13%

Insights

In beta
Mar 2019 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2025
Number of Employees
Number ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Number of Product Registrations
Number
Presence in Countries
Number
Capacity Utilization - Oncology
% ・Standalone data
Revenue Share - Oncology (Half-Yearly)
%
Capacity Utilization - Non-Oncology
% ・Standalone data
Number of Dossiers Filed (In Process)
Number
Number of International Partner Networks
Number
Number of Marketing Authorisations (MAs) Granted
Number
Oncology Annual Production Capacity - Capsules
Million Units ・Standalone data
Oncology Annual Production Capacity - Injections (Vials)
Million Units ・Standalone data
Oncology Annual Production Capacity - Tablets
Million Units ・Standalone data
Oncology API Annual Production Capacity
Metric Tons ・Standalone data
Revenue Share - Own Brand Exports
%
Working Capital Cycle
Days

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
60.72% 54.15% 53.15% 53.15% 53.15% 53.15% 53.58% 53.58% 52.86% 52.86% 52.86% 52.86%
15.74% 14.03% 13.76% 13.52% 13.52% 13.42% 13.58% 13.61% 13.41% 13.31% 13.05% 12.94%
0.00% 10.82% 10.62% 10.62% 10.62% 10.62% 10.88% 10.97% 11.25% 11.43% 11.36% 11.32%
23.54% 21.00% 22.47% 22.71% 22.71% 22.80% 21.96% 21.85% 22.48% 22.41% 22.73% 22.87%
No. of Shareholders 6,0567,2997,0017,3867,3137,8678,5988,6088,1157,5657,0699,580

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls